

contact:

cancer centre Hirslanden Zürich
 Witellikerstrasse 40
 8032 Zürich
 Phone +41 44 387 96 62
tumorzentrum.hirslanden@hirslanden.ch

open studies

	<u>name of study</u>	<u>target group/ short description</u>
breast cancer	CAMBRIA-2 study EKIB study ELEGANT study IZABRIGHT-Breast01 study MELODY-study TAXIS-study (SAKK 23/16) TroFuse-010 study TroFuse-012 study VISION-study (SAKK 23/18)	An adjuvant endocrine-based therapy study of camizestrant (AZD9833) in ER+/HER2-early breast cancer (CAMBRIA-2). Analysis of human breast tumor heterogeneity and immune cell infiltrates and their relevance for patient outcome by mass cytometry. A study of Elacestrant vVersus standard endocrine therapy in women and men with ER+,HER2-, early breast cancer with high risk of recurrence (ELEGANT) A study of Izalontamab Brengitecan versus chemotherapy in participants with previously untreated, locally advanced, recurrent inoperable, or metastatic triple-negative breast cancer ineligible for anti-PD(L)1 drugs (IZABreast01). A prospective, non-interventional, multicenter cohort study to investigate various imaging-guided techniques for the localization of malignant breast lesions. Tailored AX illary Surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS). A study of Sacituzumab Tirumotecan as a single agent and in combination with Pembrolizumab versus treatment of physician's choice in participants with HR+/HER2- unresectable locally advanced or metastatic breast cancer (VISION I). A study of Sacituzumab Tirumotecan (MK-2870) plus Pembrolizumab versus TPC in TNBC who did not achieve pCR (MK-2870-012). Vacuum assisted biopsy immediately before surgery as an intra- or pre-operative surrogate for patient response to neoadjuvant chemotherapy for breast cancer (VISION I).
urogenital tumors	IMDC Nierenregister IOSI_PROGREM Studie PCO Studie (Prostate Cancer Outcome) REVEAL Studie	International metastatic renal Cell Carcinoma Database Consortium. A retrospective study: Identification of pathogenic germline variants by germline-focused tumor analysis in a European study of high-risk and advanced prostate cancer patients. Patient reported outcome measurement of patients with prostate cancer with global uniform patient questionnaire. Swiss real world registry for first line combination treatment of Enfortumab VE dotin And Pembrolizumab in metastatic urothelial cancer- REVEAL
gastrointestinal tumors	EDIUM study ESODATA study PREFER-study Quality assurance study for duodenal tumors Quality assurance study for pancreatic tumors ROBOT-2 study Tiger study	Patient-reported outcome study for colon cancer patients: Ergebnisqualität bei Darmkrebs: Identifikation von Unterschieden und Massnahmen zur flächendeckenden Qualitätsentwicklung (Quality of Experience in the colon cancer: identification of differences und actions to be taken for a comprehensive quality development). International standardized online database für outcomes of the patients receiving evaluation and/ or treatment für esophageal diseases of benign and malignant conditions. Endoscopic management of patients with T1bN0M0 esophageal adenocarcinoma. Quality assurance study of perioperative morbidity and post-surgical follow up of hepato-duodeno-pancreatic surgery. Quality assurance study of perioperative morbidity and post-surgical follow up of pancreatic surgery. Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus minimally invasive esophagectomy for resectable esophageal adenocarcinoma, a randomized controlled trial. Distribution of lymph node metastases in esophageal carcinoma.
hematological systemic diseases	EBMT-Register MoMMent Treg-cell study SAKK EMCL-Registry	Registry for patients that received a haematopoietic stem cell transplantation or CAR T-cell therapy. Study of patients with relapsed or refractory Multiple Myeloma receiving talquetamab. Regulatory T-cells as tumor-promoting cellular partners and potential therapeutic targets in diffuse large B-cell lymphoma. The registry of the European Mantle Cell Lymphoma study group - MCL: Disease pattern, treatment algorithms and mechanisms of relapse.
neuro-oncological tumors	LGG Studie Sinonasale QoL Studie	Prospective observational study on guideline-based therapy in astrocytomas and oligodendrogliomas, WHO grade 2, with IDH1/2 mutation. Prospective observational study to evaluate the nasal quality of life after endoscopic transnasal surgeries.
multi-organ studies	Roche GLYCART Studie	Ex vivo modeling of fresh tumor tissue.